To counteract the rise of multidrug-resistant bacteria, Bruker is dedicated to developing new solutions to keep pace. The rapid identification and determination of resistance is a crucial basis for clinicians and physicians to provide their patients as quickly as possible with the antibiotic that promises rapid, gentle and appropriate treatment.
The MBT STAR®-Cepha IVD Assay, Bruker's latest development, makes a valuable contribution to this critical topic as it detects resistances towards 3rd generation cephalosporins within just one hour after a positive blood culture alert.
Together with the IVD MALDI Biotyper®, the MBT STAR®-Cepha IVD Kit enables detection of the characteristic enzymatic hydrolysis of the β-lactam ring of 3rd generation cephalosporin antibiotics. The level of hydrolysis is measured by acquisition of mass spectra in the typical mass range of the antibiotic. The assay allows detection of most actively expressed ESBL and AmpC β-lactamases in multidrug-resistant Gram-negative Enterobacterales:
Starting from a positively flagged blood culture, processed by the rapid Sepsityper® workflow, or a (sub)culture plate, results are typically available within 60 minutes.
For this purpose, bacteria are incubated with a benchmark 3rd generation cephalosporin antibiotic, conveniently provided in a microtiter plate contained in the kit.
After an assay incubation period of 30 minutes, aliquots are transferred onto a MALDI target plate, covered with dedicated MBT STAR® Matrix, and analyzed at the level of the antibiotic, using the IVD MALDI Biotyper® mass spectrometer.
